Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance

  • GLPG0778 shows statistically significant and selective effects on biomarkers in healthy volunteers
  • Further information available on safety, tolerability and dosing profile
  • Galapagos receives € single-digit millions milestone payment 

Mechelen, Belgium; 19 December 2011 – Galapagos NV (Euronext: GLPG) announced today that investigational medicine GLPG0778, which is part of its immuno-inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers.  The study also provided information on the safety and pharmacokinetic (PK) profile of GLPG0778. 

Galapagos conducted the Phase I study in 45 healthy volunteers divided into 5 cohorts, receiving in total 4 different dosages for 2 weeks.  GPLG0778 showed dose-dependent, statistically-significant and selective suppression of an induced inflammatory response in the volunteers, indicating specific inhibition of the medicine’s target in vivo.  In addition to measuring the biomarker response, the study also provided information on the safety, tolerability and PK of GLPG0778.  GSK has determined that these results meet the criteria of clinical Proof of Mechanism, thereby triggering a € single-digit millions payment to Galapagos.  GSK now has 90 days to evaluate these results and determine whether to exercise its exclusive option to in-license GLPG0778 and its corresponding back-up compounds, including GLPG0555. 

“GLPG0778 is Galapagos’ second candidate drug to show targeted activity in clinical trials this year and our first alliance program to deliver clinical Proof-of Mechanism results,” said Onno van de Stolpe, CEO of Galapagos.  “We believe GLPG0778’s biomarker and safety profile support its further development in a Phase II clinical study in a patient population.”

About Galapagos’ immuno-inflammation alliance with GlaxoSmithKline
Galapagos and GSK initiated an alliance to discover and develop disease-modifying drugs for GSK’s global R&D organization in June 2006.  Subject to achievement of certain milestone events Galapagos has the potential to receive more than €200 million in total milestone payments, plus up to double-digit royalties from GSK.  GSK has an exclusive option to further develop and commercialize compounds from the alliance on a worldwide basis.  Since the start of the immuno-inflammation alliance, Galapagos has received more than €64 million in payments from GSK.

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with seven programs in development and over 50 discovery programs.  The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:


Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.